Pitching a healthcare stock

Why this question is a favorite in healthcare superdays

"Pitch me a stock" is a standard superday question across every coverage group, but healthcare interviewers use it with particular intent, because it's an unusually clean way to test whether a candidate actually understands the sector's structure or has just memorized a generic pitch template. A candidate who applies the same pitch skeleton, current multiple, growth rate, target multiple, upside, to a pre-revenue biotech that has neither earnings nor a multiple to speak of will expose the gap immediately. A strong healthcare pitch has to start by identifying what kind of company this actually is, and only then choosing the right tools to build the rest of the case.

The structure of a healthcare stock pitch

The underlying skeleton of a good pitch doesn't change much by sector: what the company does, why it's mispriced, what catalyst will close the gap, how you'd value it, and what could go wrong. What changes in healthcare is the substance inside each piece, and getting that substance right, rather than the skeleton itself, is what separates a strong pitch from a generic one.

Step one: identify what kind of company this actually is

Before building any part of the case, place the company correctly within the sub-sector map covered in the healthcare sub-sector map, because that placement determines almost everything that follows. Is this a clinical-stage biopharma company with no revenue, a commercial-stage biopharma company with an approved product, a medtech company with a recurring consumables base, a provider business driven by volume and reimbursement rate, or a payor managing a medical loss ratio? Each of these calls for a genuinely different valuation approach and a different kind of catalyst, and getting this placement wrong at the outset undermines everything built on top of it, no matter how polished the rest of the pitch sounds.

Step two: build a thesis around a real mechanism

The strongest healthcare theses are built around one of a small number of well-understood mechanisms, rather than a vague claim that a company is "undervalued." A pipeline catalyst thesis argues that the market is underpricing the probability of success for an upcoming clinical trial or regulatory decision, relative to your own read of the available data, and it lives or dies on being specific about what data supports your view and why the market might be wrong, a case built using the risk-adjusted framework in how biotech companies are valued.

A patent-cliff protection thesis argues that a pharma company's pipeline is stronger than the market gives it credit for relative to its upcoming patent expirations, meaning the market is underestimating how well the company will replace revenue that's scheduled to decline, a case built using the mechanics in pharma business models, pipelines, and patent cliffs. A reimbursement tailwind thesis argues that a services or medtech company will benefit from an improving reimbursement environment for its specific procedures or products, an angle grounded in the volume-and-rate framework from healthcare services: providers and payors. Each of these gives an interviewer something concrete to probe, which is exactly what makes them stronger than a thesis built on a vague sense that a stock "looks cheap."

Step three: match the valuation method to the business

This is the single most common place healthcare stock pitches fall apart, and interviewers know it, which is why they probe here hardest. Applying a P/E multiple to a pre-revenue biotech is a hard stop for most interviewers, since there's no earnings for the multiple to apply to in the first place. Applying a pure rNPV approach to a mature, profitable medtech company, meanwhile, is unnecessary and signals that you don't understand why rNPV exists specifically to handle binary, pre-revenue risk rather than being a universal healthcare valuation tool. The right approach is always to ask what kind of uncertainty actually dominates this specific company's value, binary and unresolved, in which case use risk-adjusted valuation, or continuous and growth-related, in which case conventional multiples and a DCF are appropriate, and to say that reasoning out loud rather than silently picking a method and hoping it's the expected one.

For a large, diversified pharma company, mention sum-of-the-parts thinking specifically: valuing the mature, already-marketed portfolio with conventional tools while valuing meaningful pipeline assets separately with a risk-adjusted approach, then combining the two, rather than forcing the whole company into a single blended growth rate that obscures what's actually driving value.

Step four: name the risks honestly, especially binary ones

A weak pitch glosses over risk or lists only generic competitive and macroeconomic risks. A strong healthcare pitch names the specific binary or structural risk that could break the thesis: a trial reading out negative, a regulatory rejection or delay, an unfavorable reimbursement decision, or a patent litigation outcome going the wrong way. Naming these risks specifically, and explaining how they'd change your view if they materialized, shows the interviewer that you understand the thesis is genuinely probabilistic rather than a sure thing, which is itself a mark of sector fluency given how much of healthcare valuation runs on pricing uncertainty rather than eliminating it.

It also helps to state, briefly, what you'd watch for that would tell you the thesis is playing out or breaking down, since that shows you're thinking about the position the way an actual investor would rather than presenting a static, one-time argument. For a pipeline catalyst thesis, that might be interim trial data or a regulatory agency's public guidance ahead of a formal decision. For a reimbursement tailwind thesis, it might be a policy proposal moving through the stages that typically precede a final coverage decision. Naming a concrete, observable signal, rather than just waiting for the final binary outcome, is a small addition that meaningfully strengthens a pitch.

A conventional example: medtech or services

Not every strong healthcare pitch needs a biopharma binary catalyst, and it's worth having a conventional example ready too, since some interviewers specifically want to see that you can build a normal, cash-flow-driven thesis as well as a probability-weighted one. A medtech pitch might argue that a company's installed base and recurring consumables revenue, covered in medtech and life science tools economics, are underappreciated relative to the market's focus on a recent slowdown in new equipment placements, arguing that the consumables stream from the existing installed base will keep growing even if new placements stay flat. This kind of pitch runs on a conventional DCF or EV/EBITDA framework and a normal growth-and-margin catalyst, like an upcoming product cycle or a reimbursement policy update, rather than a single binary event, and it's a useful pitch to have ready specifically because it shows range: you can build a case with or without a clinical trial at the center of it.

Where to actually find a pitch idea

A common failure mode is walking into the pitch question with no real idea prepared and trying to construct one on the spot from a company you barely know. The better approach is to build a small mental list ahead of time, sourced the way an actual healthcare analyst would source ideas: following a handful of companies' upcoming clinical trial and regulatory catalysts, tracking which large pharma products are approaching a known patent expiration and whether the company's pipeline looks thin or strong relative to that timeline, and paying attention to reimbursement policy discussions that could affect a services or medtech company's growth. None of this requires access to anything beyond public company disclosures and general financial news, and having two or three ideas prepared this way, one biopharma, one more conventional, going into an interview season is far more useful than trying to improvise a pitch from a company you've never actually looked at closely.

Long versus short: healthcare gives you real material for both

Healthcare is a productive sector for a short thesis too, which is worth knowing since some interviewers specifically ask for a short pitch to see whether a candidate can argue against a popular narrative. A short thesis might argue that the market is overestimating a pipeline asset's probability of success relative to the underlying data, that a company's growth has been driven mostly by a rate increase that won't repeat rather than durable volume growth, covered in healthcare services: providers and payors, or that a company's pipeline is too thin to offset an approaching patent cliff. Each of these mirrors a long thesis mechanism run in reverse, which is a useful way to prepare: for every long thesis structure you build, think through what the corresponding short version would look like.

Practice question

Pitch me a healthcare stock, long or short, your choice.

I'd pitch a hypothetical mid-cap pharma company long, on the thesis that the market is undervaluing its late-stage pipeline relative to how exposed its current revenue is to an approaching patent cliff on its largest product. The bear case on this kind of company is usually built around the cliff itself, a meaningful share of revenue declining once exclusivity ends, but I'd argue the market isn't giving enough credit to a pipeline asset in late-stage trials that could largely offset that decline if it succeeds, since it's already cleared most of its scientific risk by reaching this stage. I'd value the on-market portfolio with a conventional multiple-based approach reflecting its declining growth profile, and I'd value the late-stage pipeline asset separately with a risk-adjusted approach given how far along it is, then combine the two using sum-of-the-parts logic rather than a single blended multiple. The catalyst would be the asset's remaining trial readout and, if positive, the subsequent regulatory decision. The key risk, which I'd name directly, is that the trial disappoints, in which case the market's original concern about the patent cliff would reassert itself with no offsetting pipeline story, and the stock would likely reprice down toward a multiple reflecting the standalone declining base.

What the interviewer is listening for: whether you match the valuation method to each piece of the business correctly, sum-of-the-parts rather than one blended approach, and whether you name the binary risk honestly rather than glossing over it. A pitch that handles both of those well demonstrates real sector fluency, independent of whether the interviewer agrees with the specific thesis.